Clinical trials
STEP 3: semaglutide plus intensive behavioral therapy
What happens when you pair the medication with intensive diet, activity and counseling support.
Quick Answer
STEP 3 (JAMA, 2021) combined once-weekly semaglutide 2.4 mg with intensive behavioral therapy (frequent counseling plus a structured low-calorie diet and activity) over 68 weeks. Mean weight reduction was about 16% with semaglutide versus about 5.7% with placebo (both groups received the intensive support). Compounded semaglutide is not FDA-approved.
Key Facts
- Semaglutide 2.4 mg + intensive behavioral therapy; 68 weeks
- Mean weight change: about −16% (semaglutide) vs −5.7% (placebo)
- Both groups received intensive counseling, diet and activity support
- Shows medication and behavior change are complementary
- Studied the branded product; compounded semaglutide is not FDA-approved
The design
STEP 3 added intensive behavioral therapy — frequent counseling sessions, an initial structured low-calorie diet, and a physical-activity program — on top of either semaglutide 2.4 mg or placebo, for 68 weeks. It tested whether maximal lifestyle support changes the medication's effect.
The results
Mean weight reduction was about 16% with semaglutide versus 5.7% with placebo. The placebo group's ~5.7% reflects the real effect of intensive lifestyle support alone; the semaglutide group's ~16% shows what the drug adds on top. It was among the largest average reductions in the STEP program.
What it means
STEP 3 reinforces that medication and behavior change are complementary, not either-or. Intensive support produces real loss on its own, and semaglutide substantially increases it. In routine care, the intensity of behavioral support varies, so real-world results differ.
Caveats
Averages mask individual variation, and the intensive support used here exceeds typical practice. The branded product was studied; compounded semaglutide is not FDA-approved.
Frequently asked questions
How much weight did people lose in STEP 3?
About 16% on average with semaglutide 2.4 mg plus intensive behavioral therapy, versus about 5.7% with placebo (who also received the intensive support).
Does this mean lifestyle change isn't needed?
No — STEP 3 shows lifestyle support produces real loss on its own and that semaglutide adds substantially to it; they work together.
References
- Wadden TA, et al. Effect of semaglutide plus intensive behavioral therapy on body weight (STEP 3). JAMA. 2021;325:1403-1413.
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
- U.S. Food and Drug Administration. Wegovy, Ozempic and Rybelsus (semaglutide) prescribing information. Novo Nordisk.
Citations are for educational reference; this article summarizes published research in plain language and is not medical advice.
Bottom Line
STEP 3 showed semaglutide plus intensive behavioral therapy produced about 16% average weight loss — evidence that medication and lifestyle change work best together.